Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fate Therapeutics, Inc.

https://fatetherapeutics.com/

Latest From Fate Therapeutics, Inc.

Working Toward A Cure: Janssen’s Multiple Myeloma Strategy

Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.

Strategy Clinical Trials

Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies

Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.

Deals Gene Therapy

KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts

Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.

Cancer Research & Development

ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies

An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.

ASCO ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Tfinity Therapeutics, Inc.
UsernamePublicRestriction

Register